What is Cardio Flow?
Cardio Flow, Inc. is at the forefront of developing advanced medical devices, specifically the FreedomFlow Orbital Atherectomy Platform. This innovative system is engineered to offer physicians a highly efficient and adaptable approach to treating complex Peripheral Artery Disease (PAD). The platform's unique mechanism of action is designed to accommodate a wide spectrum of vessel diameters, thereby optimizing clinical workflow and reducing costs for healthcare institutions. Cardio Flow's technology aims to enhance the treatment of multiple blockages and lesions, with a broader mission to decrease PAD-related amputations through cutting-edge medical solutions.
How much funding has Cardio Flow raised?
Cardio Flow has raised a total of $4.3M across 1 funding round:
Unspecified
$4.3M
Unspecified (2019): $4.3M, investors not publicly disclosed
What's next for Cardio Flow?
The substantial enterprise-level capital infusion positions Cardio Flow for accelerated growth and market penetration. This strategic backing is likely to fuel further research and development, expand manufacturing capabilities, and bolster commercialization efforts for the FreedomFlow Orbital Atherectomy Platform. The company is poised to enhance its market presence and solidify its role as a key innovator in the treatment of Peripheral Artery Disease, potentially leading to broader adoption of its technology in healthcare systems worldwide.
See full Cardio Flow company page
